Novo Nordisk has announced positive results from a phase 3 trial with long-acting factor IX, glycopegylated recombinant factor IX (N9-GP), for treatment of haemophilia B.
The paradigm 2 multi-centre, blinded trial was designed to assess the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in haemophilia B patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen said the strong results from the trial could represent a paradigm shift in the treatment of haemophilia B.
"The trial demonstrated that once-weekly prophylactic administration of N9-GP can reduce the risk of bleeds by more than 90% compared to on-demand treatment and enable 99% of the few occurring bleeds to be stopped with a single dose," Thomsen added.
The study treated 74 patients for six months on-demand, or 12 months by a prophylactic regimen of 40 U/kg or 10 U/kg N9-GP once a week.
The median bleeding rate of 15.6 episodes per year was noted for patients treated on-demand.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataA median annualised bleeding rate of 1.0 and 2.9 episodes per year was noted for patients on prophylaxis, when treated with weekly doses of 40 U/kg and 10 U/kg, respectively.
In the group of patients randomised to receive 40 U/kg N9-GP, 99% of bleeding episodes were treated with only one infusion, and two-thirds experienced complete resolution of bleeding in their target joints, and an improvement in quality of life during the trial was observed.
A steady state half-life of 110 hours was documented in pharmacokinetic data.
N9-GP was safe and well-tolerated in the trial and no patients developed inhibitors, and no apparent differences between the treatment groups with respect to adverse events and standard safety parameters were observed.
